Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

Because the efficacy of new drugs reported in trials may not translate into similar results when used in the real‐life, we analyzed the efficacy of idelalisib and rituximab (IR) in 149 patients with relapsed/refractory chronic lymphocytic leukemia treated at 34 GIMEMA centers. Median progression‐fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigolin, Gian Matteo, Cavazzini, Francesco, Piciocchi, Alfonso, Arena, Valentina, Visentin, Andrea, Reda, Gianluigi, Zamprogna, Giulia, Cibien, Francesca, Vitagliano, Orsola, Coscia, Marta, Farina, Lucia, Gaidano, Gianluca, Murru, Roberta, Varettoni, Marzia, Paolini, Rossella, Sportoletti, Paolo, Pietrasanta, Daniela, Molinari, Anna Lia, Quaglia, Francesca M., Laurenti, Luca, Marasca, Roberto, Marchetti, Monia, Mauro, Francesca R., Crea, Enrico, Vignetti, Marco, Gentile, Massimo, Montillo, Marco, Foà, Robin, Cuneo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451799/
https://www.ncbi.nlm.nih.gov/pubmed/33739461
http://dx.doi.org/10.1002/hon.2861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451799/
https://www.ncbi.nlm.nih.gov/pubmed/33739461
http://dx.doi.org/10.1002/hon.2861

Ejemplares similares